LONDON, Jan. 10, 2022 /PRNewswire/ -- Hikma
Pharmaceuticals PLC ("Hikma"), the multinational pharmaceutical
company, announces the launch of Hikma 503B – a new outsourced sterile compounding
business focused on providing high quality, ready-to-administer
injectable medications that are customized to the specific needs of
patients in the United States.
Sterile compounding – the process of combining, mixing, or
altering ingredients to create medications in ready-to-administer
formats tailored to the needs of health care providers – is an
important specialized approach to drug manufacturing that serves a
critical role in patient care. Hospital pharmacists, physicians and
nurses increasingly need these medicines, resulting in a growing US
market for outsourced compounded sterile injectable medications
that is now estimated to exceed $2
billion annually.
The launch of Hikma 503B builds on
the company's expertise and position as a leading supplier of
injectable medicines to US hospitals with a strong reputation for
quality and reliability. Today, Hikma is the second-largest
supplier by volume of generic injectables to US hospitals, and one
out of every six generic injectable medicines used by US hospitals
is a Hikma product. The company's extensive supplier relationships
and access to raw materials also provide a unique point of
differentiation to existing players in the outsourced sterile
compounding space.
"Hikma 503B is a natural extension
of our injectables business, building on our strong relationships
with US hospitals and excellent quality manufacturing protocols to
provide urgently needed product offerings to patients and health
care providers in the US," said Riad Mishlawi, President,
Injectables, Hikma. "There is substantial demand for outsourced
sterile compounded medicines among the thousands of hospitals we
currently serve, representing a large opportunity to meet a growing
and not fully met need within the US health care system. Hikma
503B is uniquely positioned to bring
pharmaceutical manufacturing standards to the space, which we
believe will establish us as a significant player in the market
over time."
Hikma 503B will operate
principally out of a 65,000 sq. ft., purpose-built facility in
Dayton, NJ, that was acquired by
Hikma in 2020. Hikma has greatly enhanced the Dayton site to create a state-of-the-art
sterile outsourced compounding and distribution facility in line
with the company's high standards of quality, adding automation and
segregation for enhanced productivity while minimizing risks.
"We are applying Hikma's expertise, talent, and engrained
commitment to quality to ensure our 503B business meets CGMP standards, which is what
the FDA requires of 503B outsourcing
facilities," said Joel Rosenstack,
Chief Commercial Officer, US Injectables, Hikma. "Our 503B business is powered by the same team and
philosophy that is behind Hikma's reputation for quality
medicines."
Hikma 503B is registering for
state licenses across the US and expects to be operating nationwide
by the end of 2022.
Enquiries
Hikma Pharmaceuticals
PLC
Investors:
Susan
Ringdal
EVP, Strategic
Planning and Global Affairs
|
+44 (0)20 7399 2760/ +44 7776 477050
uk-investors@hikma.uk.com
|
|
|
Media:
Teneo (UK
media)
Charles
Armitstead
|
+44 (0)7703 330
269
|
|
|
US
Media
|
|
Steve
Weiss
David
Belian
US Communications and
Public Affairs
|
+1 732 788
8279 +1 848 254
4875 uscommunications@hikma.com
|
About Hikma
(LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated BBB-/stable
S&P and BBB-/stable Fitch)
Hikma helps put better health within reach every day for millions
of people around the world. For more than 40 years, we've been
creating high-quality medicines and making them accessible to the
people who need them. Headquartered in the UK, we are a global
company with a local presence across the
United States (US), the Middle
East and North Africa
(MENA) and Europe, and we use our
unique insight and expertise to transform cutting-edge science into
innovative solutions that transform people's lives. We're committed
to our customers, and the people they care for, and by thinking
creatively and acting practically, we provide them with a broad
range of branded and non-branded generic medicines. Together, our
8,600 colleagues are helping to shape a healthier world that
enriches all our communities. We are a leading licensing partner,
and through our venture capital arm, are helping bring innovative
health technologies to people around the world. For more
information, please visit: www.hikma.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/hikma-launches-new-503b-sterile-compounding-business-301456431.html
SOURCE Hikma Pharmaceuticals USA Inc.